BASILEA PHARMACEUTICA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.3 CHF | +0.12% |
|
-1.10% | +14.16% |
| Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
| Apr. 04 | Stocks Close in Green as Swiss Inflation Unexpectedly Slows | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 503.1 | 574.2 | 484.7 | 545.8 | 422.9 | 483.7 | - | - |
| Enterprise Value (EV) 1 | 539.8 | 646.6 | 552.8 | 630 | 473.9 | 541.6 | 496.2 | 405.3 |
| P/E ratio | -22.5 x | -37.2 x | -70.6 x | 44.9 x | 41 x | 20.2 x | 17 x | 6.78 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.74 x | 4.5 x | 3.27 x | 3.69 x | 2.68 x | 2.66 x | 2.35 x | 2.05 x |
| EV / Revenue | 4.02 x | 5.07 x | 3.73 x | 4.26 x | 3.01 x | 2.98 x | 2.41 x | 1.72 x |
| EV / EBITDA | -34.7 x | -29.3 x | 287 x | 32.1 x | 22.8 x | 16.3 x | 10.3 x | 5.03 x |
| EV / FCF | -8.4 x | -11.5 x | -16.8 x | 168 x | 35.9 x | 36.8 x | 11.1 x | 4.45 x |
| FCF Yield | -11.9% | -8.72% | -5.94% | 0.6% | 2.79% | 2.71% | 9.05% | 22.5% |
| Price to Book | -5.43 x | -5.36 x | - | - | -42.3 x | 32 x | 8.67 x | 3.19 x |
| Nbr of stocks (in thousands) | 10,737 | 10,803 | 11,844 | 11,918 | 11,980 | 12,003 | - | - |
| Reference price 2 | 46.86 | 53.15 | 40.92 | 45.80 | 35.30 | 40.30 | 40.30 | 40.30 |
| Announcement Date | 2/18/20 | 2/16/21 | 2/15/22 | 2/14/23 | 2/13/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 134.4 | 127.6 | 148.1 | 147.8 | 157.6 | 181.7 | 205.6 | 235.7 |
| EBITDA 1 | -15.56 | -22.07 | 1.926 | 19.64 | 20.78 | 33.21 | 48.21 | 80.53 |
| EBIT 1 | -17.2 | -8.222 | 1.2 | 18.5 | 19.2 | 31.2 | 37.65 | 72.45 |
| Operating Margin | -12.8% | -6.44% | 0.81% | 12.52% | 12.18% | 17.17% | 18.31% | 30.74% |
| Earnings before Tax (EBT) 1 | -22.38 | -14.67 | -6.795 | 12.1 | 10.46 | 23.74 | 38.39 | 82.65 |
| Net income 1 | -22.4 | -14.72 | -6.8 | 12.15 | 10.5 | 22.98 | 35.14 | 75.57 |
| Net margin | -16.67% | -11.53% | -4.59% | 8.22% | 6.66% | 12.64% | 17.09% | 32.06% |
| EPS 2 | -2.080 | -1.430 | -0.5800 | 1.020 | 0.8600 | 1.994 | 2.364 | 5.940 |
| Free Cash Flow 1 | -64.24 | -56.4 | -32.86 | 3.753 | 13.21 | 14.7 | 44.9 | 91 |
| FCF margin | -47.8% | -44.19% | -22.19% | 2.54% | 8.38% | 8.09% | 21.83% | 38.61% |
| FCF Conversion (EBITDA) | - | - | - | 19.11% | 63.57% | 44.26% | 93.14% | 113.01% |
| FCF Conversion (Net income) | - | - | - | 30.9% | 125.82% | 63.97% | 127.77% | 120.42% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/18/20 | 2/16/21 | 2/15/22 | 2/14/23 | 2/13/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 71.2 | 69.3 | 58.3 | 54.2 | 93.9 | 58.65 | 89.15 | 84.9 | 72.7 | 85.86 | 95.33 |
| EBITDA 1 | - | - | - | - | - | - | - | - | -16.87 | 12.92 | 17.99 |
| EBIT 1 | -4 | 12.8 | -21.04 | -15.4 | 16.6 | -9.041 | 27.54 | 36.9 | -17.7 | 14.96 | 15 |
| Operating Margin | -5.62% | 18.47% | -36.08% | -28.41% | 17.68% | -15.42% | 30.89% | 43.46% | -24.35% | 17.42% | 15.73% |
| Earnings before Tax (EBT) 1 | -6.97 | 9.973 | -24.64 | -19.88 | 13.08 | -12.22 | 24.32 | 31.87 | -21.41 | 12.41 | 14.57 |
| Net income 1 | -7 | 9.9 | -24.66 | -19.9 | 13.1 | -12.21 | 24.36 | 31.8 | -21.3 | 11.71 | 13.36 |
| Net margin | -9.83% | 14.29% | -42.3% | -36.72% | 13.95% | -20.82% | 27.32% | 37.46% | -29.3% | 13.64% | 14.02% |
| EPS 2 | -0.6400 | 0.9100 | -2.340 | -1.840 | 1.260 | -1.030 | 2.050 | 2.420 | -1.560 | 0.9414 | 1.055 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/18/20 | 8/11/20 | 2/16/21 | 8/17/21 | 2/15/22 | 8/16/22 | 2/14/23 | 8/15/23 | 2/13/24 | - | - |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 36.7 | 72.4 | 68.1 | 84.2 | 51 | 57.9 | 12.5 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | 78.4 |
| Leverage (Debt/EBITDA) | -2.358 x | -3.28 x | 35.36 x | 4.286 x | 2.453 x | 1.743 x | 0.2595 x | - |
| Free Cash Flow 1 | -64.2 | -56.4 | -32.9 | 3.75 | 13.2 | 14.7 | 44.9 | 91 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | 437% | 117% | 80.3% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | -8.630 | -9.930 | - | - | -0.8300 | 1.260 | 4.650 | 12.60 |
| Cash Flow per Share 2 | - | - | - | - | 1.170 | 1.780 | 0.1700 | 3.950 |
| Capex 1 | 0.4 | 2.27 | 0.86 | 3.3 | 1.03 | 1.2 | 1.9 | 2.5 |
| Capex / Sales | 0.3% | 1.77% | 0.58% | 2.23% | 0.66% | 0.66% | 0.92% | 1.06% |
| Announcement Date | 2/18/20 | 2/16/21 | 2/15/22 | 2/14/23 | 2/13/24 | - | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
40.3
CHF
Average target price
70.58
CHF
Spread / Average Target
+75.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.16% | 529M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BSLN Stock
- Financials Basilea Pharmaceutica AG
